Min-Hu Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8340520/publications.pdf

Version: 2024-02-01

69 papers

2,678 citations

331670 21 h-index 206112 48 g-index

70 all docs

70 docs citations

70 times ranked

4800 citing authors

#	Article	IF	CITATIONS
1	Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease. Gut, 2022, 71, 55-67.	12.1	33
2	Reverse translation approach generates a signature of penetrating fibrosis in Crohn's disease that is associated with anti-TNF response. Gut, 2022, 71, 1289-1301.	12.1	9
3	Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases. Physiological Reviews, 2022, 102, 605-652.	28.8	31
4	Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Medical Internet Research, 2022, 24, e28978.	4.3	19
5	Systematic review with metaâ€analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Alimentary Pharmacology and Therapeutics, 2022, 55, 266-276.	3.7	30
6	Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients With Crohn's Disease: A Pilot Study. Inflammatory Bowel Diseases, 2022, 28, S67-S75.	1.9	7
7	Cost-efficient snare-assisted peroral endoscopic myotomy in comparison of conventional endoscopic knife for treatment of achalasia: results of a randomized controlled trial. Ecological Management and Restoration, 2022, , .	0.4	1
8	Chinese Consensus Report on Family-Based <i>Helicobacter pylori </i> Infection Control and Management (2021 Edition). Gut, 2022, 71, 238-253.	12.1	81
9	Dietary inflammatory potential mediated gut microbiota and metabolite alterations in Crohn's disease: A fire-new perspective. Clinical Nutrition, 2022, 41, 1260-1271.	5.0	14
10	The efficacy and safety of keverprazan, a novel potassiumâ€competitive acid blocker, in treating erosive oesophagitis: a phase <scp>III < scp>, randomised, doubleâ€blind multicentre study. Alimentary Pharmacology and Therapeutics, 2022, 55, 1524-1533.</scp>	3.7	12
11	Intestinal strictures in Crohn's disease: a 2021 update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211049.	3.2	9
12	The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211023.	3.2	8
13	Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterology Report, 2021, 9, 329-338.	1.3	3
14	Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. Clinical Colorectal Cancer, 2021, 20, 177-185.e13.	2.3	23
15	Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. Endoscopy, 2021, 53, 702-709.	1.8	7
16	Impact of COVIDâ€19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 700-709.	2.8	17
17	Herbal medicines in functional dyspepsia—Untapped opportunities not without risks. Neurogastroenterology and Motility, 2021, 33, e14044.	3.0	11
18	Knowledge, Attitude, and Practice Survey of Gastroparesis in Asia by Asian Neurogastroenterology and Motility Association. Journal of Neurogastroenterology and Motility, 2021, 27, 46-54.	2.4	9

#	Article	IF	CITATIONS
19	Degree of Creeping Fat Assessed by Computed Tomography Enterography is Associated with Intestinal Fibrotic Stricture in Patients with Crohn's Disease: A Potentially Novel Mesenteric Creeping Fat Index. Journal of Crohn's and Colitis, 2021, 15, 1161-1173.	1.3	45
20	Implications of COVID-19 for patients with pre-existing digestive diseases: an update. The Lancet Gastroenterology and Hepatology, 2021, 6, 258-260.	8.1	4
21	Noncoding RNAs as Promising Diagnostic Biomarkers and Therapeutic Targets in Intestinal Fibrosis of Crohn's Disease: The Path From Bench to Bedside. Inflammatory Bowel Diseases, 2021, 27, 971-982.	1.9	10
22	Prealbumin and Retinol-Binding Protein 4: The Promising Inflammatory Biomarkers for Identifying Endoscopic Remission in Crohn's Disease. Journal of Inflammation Research, 2021, Volume 14, 7371-7379.	3.5	2
23	Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut, 2020, 69, 224-230.	12.1	81
24	Magnetisation transfer imaging adds information to conventional MRIs to differentiate inflammatory from fibrotic components of small intestinal strictures in Crohn's disease. European Radiology, 2020, 30, 1938-1947.	4.5	21
25	Impact of COVID-19 on the Healthcare of Patients With Inflammatory Bowel Disease: A Comparison Between Epicenter vs. Non-epicenter Areas. Frontiers in Medicine, 2020, 7, 576891.	2.6	5
26	Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093896.	3.2	16
27	Snare-tip-assisted peroral endoscopic myotomy for achalasia (with video). Gastroenterology Report, 2020, 8, 329-330.	1.3	1
28	Classifying Crohn's disease into colon-involving versus non-colon-involving groups is a better predictor of clinical outcomes than the Montreal classification. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096873.	3.2	3
29	Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19. Gastroenterology, 2020, 159, 1170-1172.e1.	1.3	59
30	Intestinal fibrosis: The Achilles heel of inflammatory bowel diseases?. Journal of Digestive Diseases, 2020, 21, 306-307.	1.5	5
31	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 667-678.	8.1	804
32	Implications of COVID-19 for patients with pre-existing digestive diseases. The Lancet Gastroenterology and Hepatology, 2020, 5, 425-427.	8.1	274
33	Responding to COVID-19: Perspectives From the Chinese Society of Gastroenterology. Gastroenterology, 2020, 158, 2024-2027.	1.3	13
34	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1330-1339.	1.9	8
35	2019 Seoul Consensus on Esophageal Achalasia Guidelines. Journal of Neurogastroenterology and Motility, 2020, 26, 180-203.	2.4	70
36	Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Frontiers in Medicine, 2020, 7, 613475.	2.6	9

#	Article	IF	CITATIONS
37	Esophageal physiologic profiles within erosive esophagitis in China: Predominantly lowâ€grade esophagitis with low reflux burden. Neurogastroenterology and Motility, 2019, 31, e13702.	3.0	19
38	Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. Cancer Medicine, 2019, 8, 5000-5011.	2.8	11
39	Percutaneous transgastric endoscopic myotomy for upper esophageal spastic stricture. Endoscopy, 2019, 51, E345-E346.	1.8	2
40	Low 6â€thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 679-685.	2.8	6
41	IVIM with fractional perfusion as a novel biomarker for detecting and grading intestinal fibrosis in Crohn's disease. European Radiology, 2019, 29, 3069-3078.	4.5	26
42	Intra-Cavitary Contrast-Enhanced Ultrasound: A Novel Radiation-Free Method for Detecting Abscess-Associated Penetrating Disease in Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 593-599.	1.3	12
43	Ability of DWI to characterize bowel fibrosis depends on the degree of bowel inflammation. European Radiology, 2019, 29, 2465-2473.	4.5	13
44	Characterization of Degree of Intestinal Fibrosis in Patients with Crohn Disease by Using Magnetization Transfer MR Imaging. Radiology, 2018, 287, 494-503.	7.3	81
45	Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2183-2190.	1.9	53
46	Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 664-670.	2.8	8
47	Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 608-614.	2.8	1
48	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. Journal of Crohn's and Colitis, 2018, 12, 1410-1417.	1.3	7
49	6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2621-2627.	1.9	13
50	Different clinical outcomes in Crohn $\hat{a} \in \mathbb{N}$ s disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype?. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481877793.	3.2	16
51	Networked Clinical Study Collaboration on Inflammatory Bowel Disease in China. American Journal of Gastroenterology, 2018, 113, 1266.	0.4	10
52	Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. Journal of Gastroenterology, 2017, 52, 535-554.	5.1	133
53	Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: AÂMeta-analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1359-1372.e6.	4.4	43
54	Urine Dripping From the Sigmoid Wall in a Patient With Suspected Crohn's Disease: An Unusual Manifestation of a Colonovesical Fistula. American Journal of Gastroenterology, 2017, 112, 680.	0.4	1

#	Article	IF	CITATIONS
55	Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target. Therapeutic Advances in Gastroenterology, 2017, 10, 453-463.	3.2	7
56	Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohnâ $€$ [™] s disease. Stem Cell Research and Therapy, 2017, 8, 136.	5.5	30
57	Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therapeutic Advances in Gastroenterology, 2017, 10, 397-406.	3.2	14
58	Adsorptive Granulocyte and Monocyte Apheresis in the Treatment of Ulcerative Colitis: The First Multicenter Study in China. Gut and Liver, 2017, 11, 216-225.	2.9	12
59	Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease. Patient Preference and Adherence, 2016, Volume 11, 23-31.	1.8	23
60	Motility characteristics in the transition zone in Gastroesophageal Reflux Disease (GORD) patients. BMC Gastroenterology, 2016, 16, 106.	2.0	3
61	Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut, 2016, 65, 1402-1415.	12.1	144
62	Intracavitary Contrast-enhanced Ultrasonography to Detect Enterovesical Fistula in Crohn's Disease. Gastroenterology, 2016, 150, 315-317.	1.3	15
63	Systematic Review with Meta-analysis of Prospective Studies: Anti-tumour Necrosis Factor for Prevention of Postoperative Crohn's Disease Recurrence. Journal of Crohn's and Colitis, 2015, 9, 918-927.	1.3	19
64	Factors associated with progression to surgery in Crohn's disease patients with endoscopic stricture. Endoscopy, 2014, 46, 956-962.	1.8	14
65	<i>Apolipoprotein C3</i> (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World Journal of Gastroenterology, 2014, 20, 14010.	3.3	28
66	Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm. International Journal of Clinical and Experimental Pathology, 2014, 7, 4204-12.	0.5	8
67	H. pylori-encoded CagA disrupts tight junctions and induces invasiveness of AGS gastric carcinoma cells via Cdx2-dependent targeting of Claudin-2. Cellular Immunology, 2013, 286, 22-30.	3.0	37
68	Prompt Upper Endoscopy Is an Appropriate Initial Management in Uninvestigated Chinese Patients With Typical Reflux Symptoms. American Journal of Gastroenterology, 2010, 105, 1947-1952.	0.4	23
69	Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: A population-based study in South China. Scandinavian Journal of Gastroenterology, 2005, 40, 759-767.	1.5	92